Endocannabinoid

The endocannabinoid system: an osteopathic perspective.
[18948642] J Am Osteopath Assoc 108(10): 586-600 (2008)

The endocannabinoid system as a novel approach for managing obesity.
[17784530] J Am Osteopath Assoc 107(4 Suppl 2): S12-20 (2007)

Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects.
[15550451] Alcohol Alcohol 40(1): 25-34 (2005)

The endocannabinoid system: physiology and pharmacology.
[15550444] Alcohol Alcohol 40(1): 2-14 (2005)

Role of the endocannabinoid system in the development of tolerance to alcohol.
[15550443] Alcohol Alcohol 40(1): 15-24 (2005)

Modulation of fear and anxiety by the endogenous cannabinoid system.
[17329982] CNS Spectr 12(3): 211-20 (2007)

Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity.
[18084639] Curr Neuropharmacol 5(2): 81-97 (2007)

The endocannabinoid system as a target for the treatment of motor dysfunction.
[19220290] Br J Pharmacol 156(7): 1029-40 (2009)

Emerging strategies for exploiting cannabinoid receptor agonists as medicines.
[19226257] Br J Pharmacol 156(3): 397-411 (2009)

The endocannabinoid system in brain reward processes.
[18414385] Br J Pharmacol 154(2): 369-83 (2008)

CB2 receptors in the brain: role in central immune function.
[18037916] Br J Pharmacol 153(2): 240-51 (2008)

Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
[18026124] Br J Pharmacol 153(2): 252-62 (2008)

Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.
[17994113] Br J Pharmacol 153(2): 319-34 (2008)

The peripheral cannabinoid receptor knockout mice: an update.
[17965741] Br J Pharmacol 153(2): 309-18 (2008)

Cannabinoid CB2 receptors in human brain inflammation.
[17934510] Br J Pharmacol 153(2): 277-85 (2008)

Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor.
[17922025] Br J Pharmacol 153(2): 271-6 (2008)

Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.
[17906679] Br J Pharmacol 153(2): 226-39 (2008)

Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation.
[17906675] Br J Pharmacol 153(2): 263-70 (2008)

CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies.
[17891163] Br J Pharmacol 153(2): 216-25 (2008)

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
[17828291] Br J Pharmacol 153(2): 199-215 (2008)

CB2 receptors in reproduction.
[17828289] Br J Pharmacol 153(2): 189-98 (2008)

Novel cannabinoid receptors.
[17906678] Br J Pharmacol 152(5): 567-75 (2007)

Cannabinoid control of neuroinflammation related to multiple sclerosis.
[17891167] Br J Pharmacol 152(5): 649-54 (2007)

The complications of promiscuity: endocannabinoid action and metabolism.
[17876303] Br J Pharmacol 152(5): 602-23 (2007)

Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.
[17828292] Br J Pharmacol 152(5): 633-48 (2007)

Endocannabinoids and the gastrointestinal tract: what are the key questions?
[17767170] Br J Pharmacol 152(5): 663-70 (2007)

Endocannabinoids and the haematological system.
[17704826] Br J Pharmacol 152(5): 671-5 (2007)

Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
[17704824] Br J Pharmacol 152(5): 576-82 (2007)

Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain.
[17704819] Br J Pharmacol 152(5): 624-32 (2007)

The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action.
[17618306] Br J Pharmacol 152(5): 594-601 (2007)

Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.
[17450170] Br J Pharmacol 151(4): 427-40 (2007)

The expanding field of cannabimimetic and related lipid mediators.
[15655504] Br J Pharmacol 144(4): 459-65 (2005)

Efficacy in CB1 receptor-mediated signal transduction.
[15308578] Br J Pharmacol 142(8): 1209-18 (2004)

The complexities of the cardiovascular actions of cannabinoids.
[15131000] Br J Pharmacol 142(1): 20-6 (2004)

Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE).
[15100161] Br J Pharmacol 142(1): 9-19 (2004)

Involvement of cannabinoid receptors in gut motility and visceral perception.
[15100166] Br J Pharmacol 141(8): 1335-45 (2004)

Cannabinoids and neuroinflammation.
[14757702] Br J Pharmacol 141(5): 775-85 (2004)

The endocannabinoid system: a general view and latest additions.
[14744801] Br J Pharmacol 141(5): 765-74 (2004)

Emerging roles for endocannabinoids in long-term synaptic plasticity.
[14504143] Br J Pharmacol 140(5): 781-9 (2003)

Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction?
[12711614] Br J Pharmacol 138(7): 1183-4 (2003)

Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.
[11408519] J Pharmacol Exp Ther 298(1): 7-14 (2001)

Endocannabinoids and vascular function.
[10871291] J Pharmacol Exp Ther 294(1): 27-32 (2000)

The endocannabinoid system as an emerging target of pharmacotherapy.
[16968947] Pharmacol Rev 58(3): 389-462 (2006)

The cannabinoid system and immune modulation.
[12960289] J Leukoc Biol 74(4): 486-96 (2003)

Cannabinoids: a new group of agonists of PPARs.
[18288264] PPAR Res 2007(-): 23513 (2007)

Review article: endocannabinoids and their receptors in the enteric nervous system.
[16197488] Aliment Pharmacol Ther 22(8): 667-83 (2005)

Endocannabinoid-mediated control of synaptic transmission.
[19126760] Physiol Rev 89(1): 309-80 (2009)

Role of endogenous cannabinoids in synaptic signaling.
[12843414] Physiol Rev 83(3): 1017-66 (2003)

The emerging role of the endocannabinoid system in endocrine regulation and energy balance.
[16306385] Endocr Rev 27(1): 73-100 (2006)

Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood.
[15792943] Exp Biol Med (Maywood) 230(4): 225-34 (2005)

Neurotransmission: emerging roles of endocannabinoids.
[16051162] Curr Biol 15(14): R549-51 (2005)

Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
[17418607] Diabetes Metab 33(2): 85-95 (2007)

Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system.
[17350871] Diabetes Metab 33(2): 97-107 (2007)

Endocannabinoids in endocrine and related tumours.
[18508995] Endocr Relat Cancer 15(2): 391-408 (2008)

Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.
[19729432] Eur J Endocrinol 161(5): 655-62 (2009)

Cannabinoids and the gastrointestinal tract.
[11358910] Gut 48(6): 859-67 (2001)

Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations.
[18779440] Hypertension 52(4): 601-7 (2008)

Role of cannabinoids in the development of fatty liver (steatosis).
[20204561] AAPS J 12(2): 233-7 (2010)

Cannabinoids, endocannabinoids, and related analogs in inflammation.
[19199042] AAPS J 11(1): 109-19 (2009)

Further advances in the synthesis of endocannabinoid-related ligands.
[16353927] AAPS J 7(2): E496-502 (2005)

The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.
[16353941] AAPS J 7(3): E625-54 (2005)

Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.
[17975129] Am J Physiol Gastrointest Liver Physiol 294(1): G9-G12 (2008)

Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis.
[18006606] Am J Physiol Gastrointest Liver Physiol 294(2): G357-62 (2008)

Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases.
[18239059] Am J Physiol Gastrointest Liver Physiol 294(4): G850-4 (2008)

Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases.
[18203843] Am J Physiol Heart Circ Physiol 294(3): H1133-4 (2008)

Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids.
[18250160] J Biol Chem 283(13): 8065-9 (2008)

Cannabinoids and innate immunity: taking a toll on neuroinflammation.
[21479354] ScientificWorldJournal 11(-): 855-65 (2011)

Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor.
[13130128] J Lipid Res 44(12): 2221-33 (2003)

Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.
[18782012] Endocr Metab Immune Disord Drug Targets 8(3): 159-72 (2008)

Signaling pathways involved in the cardioprotective effects of cannabinoids.
[17031075] J Pharmacol Sci 102(2): 155-66 (2006)

Endocannabinoid signalling: has it got rhythm?
[20590563] Br J Pharmacol 160(3): 530-43 (2010)

Phytocannabinoids beyond the Cannabis plant - do they exist?
[20590562] Br J Pharmacol 160(3): 523-9 (2010)

The endocannabinoid system as a target for the treatment of neurodegenerative disease.
[20590559] Br J Pharmacol 160(3): 480-98 (2010)

CB2: a cannabinoid receptor with an identity crisis.
[20590558] Br J Pharmacol 160(3): 467-79 (2010)

Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls.
[20590555] Br J Pharmacol 160(3): 423-42 (2010)

Prostamides (prostaglandin-ethanolamides) and their pharmacology.
[17721551] Br J Pharmacol 153(3): 410-9 (2008)

Cannabinoids for cancer treatment: progress and promise.
[18199524] Cancer Res 68(2): 339-42 (2008)

Endocannabinoids--the brain's own marijuana--may be linked to the metabolic syndrome.
[17415289] MedGenMed 8(4): 7 (2006)

Serotonin, the prefrontal cortex, and the antidepressant-like effect of cannabinoids.
[18057193] J Neurosci 27(49): 13369-70 (2007)

The endocannabinoid system: a new perspective for cardiometabolic risk control.
[17128328] Arq Bras Cardiol 87(4): 548-58 (2006)

Signaling via CNS cannabinoid receptors.
[18336996] Mol Cell Endocrinol 286(1-2 Suppl 1): S60-5 (2008)

Aspects of endocannabinoid signaling in periimplantation biology.
[18294762] Mol Cell Endocrinol 286(1-2 Suppl 1): S3-11 (2008)

Pharmacological characterization of GPR55, a putative cannabinoid receptor.
[20298715] Pharmacol Ther 126(3): 301-13 (2010)

Minireview: Endocannabinoids and their receptors as targets for obesity therapy.
[19372200] Endocrinology 150(6): 2531-6 (2009)

Role of endocannabinoids in regulating drug dependence.
[19300605] Neuropsychiatr Dis Treat 3(6): 711-21 (2007)

Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine.
[19226289] Br J Pharmacol 156(5): 740-50 (2009)

A putative 'pre-nervous' endocannabinoid system in early echinoderm development.
[19907129] Dev Neurosci 32(1): 1-18 (2010)

Localization of the endocannabinoid-degrading enzyme fatty acid amide hydrolase in rat dorsal root ganglion cells and its regulation after peripheral nerve injury.
[19321773] J Neurosci 29(12): 3766-80 (2009)

Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors.
[16284279] J Pharmacol Exp Ther 316(3): 969-82 (2006)

Tempo and mode in the endocannaboinoid system.
[17676365] J Mol Evol 65(3): 267-76 (2007)

(Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells.
[19255745] Naunyn Schmiedebergs Arch Pharmacol 380(1): 67-77 (2009)

The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.
[19608284] Trends Pharmacol Sci 30(8): 411-20 (2009)

Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.
[20133390] Pharmacol Rev 62(1): 136-54 (2010)

The endocannabinoid system: potential for reducing cardiometabolic risk.
[19373218] Obesity (Silver Spring) 17(10): 1821-9 (2009)

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.
[18076956] Physiol Behav 93(4-5): 666-70 (2008)

Understanding functional residues of the cannabinoid CB1.
[20370713] Curr Top Med Chem 10(8): 779-98 (2010)

Endocannabinoid system involvement in brain reward processes related to drug abuse.
[17936009] Pharmacol Res 56(5): 393-405 (2007)

Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence.
[17945506] Pharmacol Res 56(5): 406-17 (2007)

Enhancement of endocannabinoid signaling and the pharmacotherapy of depression.
[17945507] Pharmacol Res 56(5): 360-6 (2007)

Endocannabinoids and immune regulation.
[19428268] Pharmacol Res 60(2): 85-92 (2009)

Endocannabinoids and cardiac contractile function: pathophysiological implications.
[19569260] Pharmacol Res 60(2): 99-106 (2009)

Endocannabinoids and the heart.
[19276990] J Cardiovasc Pharmacol 53(4): 267-76 (2009)

Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch.
[18295199] Eur J Pharmacol 583(2-3): 322-39 (2008)

The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism.
[17692039] Mini Rev Med Chem 7(8): 769-79 (2007)

Endocannabinoids: stress, anxiety, and fear.
[19622681] J Neuropsychiatry Clin Neurosci 21(2): iv, 109-13 (2009)

Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown.
[18760289] Neuropharmacology 55(7): 1095-104 (2008)

The elmiric acids: biologically active anandamide analogs.
[18187165] Neuropharmacology 55(8): 1259-64 (2008)

Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.
[20468046] Glia 58(9): 1017-30 (2010)

The endocannabinoid system and pain.
[19839937] CNS Neurol Disord Drug Targets 8(6): 403-21 (2009)

Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids.
[19903506] Prog Neuropsychopharmacol Biol Psychiatry 34(5): 791-7 (2010)

The emerging role of the endocannabinoid system in cardiovascular disease.
[19357846] Semin Immunopathol 31(1): 63-77 (2009)

Hypothalamic regulation of bone.
[20660619] J Mol Endocrinol 45(4): 175-81 (2010)

AMPK as a mediator of hormonal signalling.
[19625456] J Mol Endocrinol 44(2): 87-97 (2010)

Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities.
[21966155] J Pharm Bioallied Sci 3(3): 350-60 (2011)

Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
[19527737] Life Sci 86(15-16): 615-23 (2010)

Cannabinoid system and cyclooxygenases inhibitors.
[21505570] J Med Life 4(1): 11-20 (2011)

In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability.
[19523530] Prostaglandins Other Lipid Mediat 91(3-4): 90-103 (2010)

Critical enzymes involved in endocannabinoid metabolism.
[17346227] Protein Pept Lett 14(3): 237-46 (2007)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Endocannabinoid.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Endocannabinoid.php on line 92